Rhumbline Advisers Raises Stock Holdings in Tempus AI, Inc. $TEM

Rhumbline Advisers significantly increased its holdings in Tempus AI by 3,633.2% in Q2. Other institutional investors also boosted their stakes. Insiders sold shares, with EVP Andrew Polovin and CFO James Rogers reducing their positions. Analysts have mixed ratings, with a consensus target price of $81.17. Tempus AI's stock opened at $74.91, with a 52-week range of $31.36 to $104.32.

Rhumbline Advisers grew its holdings in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 3,633.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 89,783 shares of the company's stock after buying an additional 87,378 shares during the quarter. Rhumbline Advisers owned 0.05% of Tempus AI worth $5,705,000 as of its most recent SEC filing.

Tempus AI: Volatility Equates to Opportunity in AI Leader

Several other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Tempus AI by 6,247.5% during the 1st quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company's stock worth $289,204,000 after buying an additional 5,900,668 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Tempus AI by 411.4% in the second quarter. Geode Capital Management LLC now owns 649,420 shares of the company's stock valued at $41,264,000 after acquiring an additional 522,443 shares in the last quarter. KADENSA CAPITAL Ltd acquired a new stake in shares of Tempus AI in the first quarter worth approximately $22,130,000. Legal & General Group Plc boosted its stake in shares of Tempus AI by 24.4% in the second quarter. Legal & General Group Plc now owns 450,645 shares of the company's stock worth $28,634,000 after acquiring an additional 88,373 shares during the last quarter. Finally, Vestmark Advisory Solutions Inc. increased its position in shares of Tempus AI by 102.5% during the second quarter. Vestmark Advisory Solutions Inc. now owns 338,241 shares of the company's stock worth $21,492,000 after purchasing an additional 171,243 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Andrew Polovin sold 12,874 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $75.00, for a total value of $965,550.00. Following the completion of the sale, the executive vice president owned 107,590 shares of the company's stock, valued at $8,069,250. This represents a 10.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO James William Rogers sold 7,257 shares of Tempus AI stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $65.54, for a total transaction of $475,623.78. Following the sale, the chief financial officer directly owned 131,216 shares in the company, valued at approximately $8,599,896.64. The trade was a 5.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 1,077,814 shares of company stock valued at $84,592,895. Company insiders own 26.27% of the company's stock.

Wall Street Analysts Forecast Growth

Tempus AI Hits $100—Are Shares Due for a Pullback?

A number of research analysts have weighed in on TEM shares. TD Cowen lowered Tempus AI from a "buy" rating to a "hold" rating and set a $88.00 price objective on the stock. in a report on Tuesday, October 21st. Needham & Company LLC upped their target price on shares of Tempus AI from $70.00 to $100.00 and gave the stock a "buy" rating in a report on Wednesday, November 5th. HC Wainwright reduced their target price on shares of Tempus AI from $98.00 to $89.00 and set a "buy" rating for the company in a research report on Friday, November 7th. Morgan Stanley raised their price target on shares of Tempus AI from $80.00 to $85.00 and gave the stock an "overweight" rating in a research note on Monday. Finally, Guggenheim upped their price objective on shares of Tempus AI from $80.00 to $95.00 and gave the company a "buy" rating in a research note on Friday, September 26th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Tempus AI presently has an average rating of "Hold" and a consensus target price of $81.17.

Read Our Latest Research Report on TEM

Tempus AI Stock Up 1.3%

These 5 Beaten-Down Tech Stocks Could Catch Fire Next

Shares of TEM opened at $74.91 on Thursday. Tempus AI, Inc. has a 52-week low of $31.36 and a 52-week high of $104.32. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45. The stock has a fifty day simple moving average of $82.14 and a two-hundred day simple moving average of $72.81. The company has a market capitalization of $13.33 billion, a PE ratio of -62.95 and a beta of 4.99.

Tempus AI (NASDAQ:TEM - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The firm had revenue of $334.21 million for the quarter, compared to analysts' expectations of $328.89 million. During the same quarter in the previous year, the company posted ($0.46) EPS. The company's revenue was up 84.7% compared to the same quarter last year. As a group, equities analysts forecast that Tempus AI, Inc. will post -6.15 EPS for the current year.

Tempus AI Profile

(Free Report)

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Should You Invest $1,000 in Tempus AI Right Now?

Before you consider Tempus AI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.

While Tempus AI currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here